Correlation between transcription factor activator protein-2β (TFAP-2β) and endometrial carcinoma

Aims: To investigate the correlation between transcription factor activator protein-2β (TFAP-2β) and endometrial carcinoma (EC). Materials and Methods: The study comprised 60 randomly selected patients diagnosed and treated at the 2nd Affiliated Hospital of Harbin Medical University from November 2011 to June 2012 for endometrial carcinoma (n = 30) and myoma of uterus (n = 30). The expression of TFAP-2β mRNA in endometrial carcinoma was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR). Body mass index (BMI), waist circumference, and venous blood samples were obtained before abdominal surgery clinically. Results: The expression of TFAP-2β mRNA in endometrial tissue of patients with EC was higher than that of normal endometrium (p < 0.05). The expression of TFAP-2β mRNA in endometrial tissue of patients with metabolism syndrome was higher than that of lean ones (p < 0.05). There was no significant difference in the expression of TFAP-2β mRNA in endometrial tissue between patients with both EC and metabolism syndrome and in those with EC only. The expression levels of TFAP-2β mRNA had positive correlation with triglyceride (r = 0.271, p < 0.05) and high-density lipoprotein (HDL) (r = 0.314, p < 0.05). There was no significant correlation between the expression of TFAP-2β mRNA and CA125, fasting plasma glucose, low-density lipoprotein (LDL), waist circumference, total cholesterol, and BMI. Conclusions: TFAP-2β constituted promoter activity in EC and also contributed to the development of the metabolic syndrome. TFAP-2β may influence the occurrence and development of EC through regulating the expression of various adipokines and lipoprotein metabolism. Probably TFAP-2β can be a candidate tumor marker for EC.

Adipokines; Endometrial carcinoma; Metabolism syndrome; Real-time RT-PCR; TFAP-2β.

[1] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics, 2002”. CA Cancer J. Clin., 2005, 55, 74.

[2] Huff J.: “IARC monographs, industry influence, and upgrading, downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer”. Int. J. Occup. Environ. Health, 2002, 8, 249.

[3] Friedenreich C.M., Biel R.K., Lau D.C., Csizmadi I., Courneya K.S., Magliocco A.M., et al.: “Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer”. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 2384.

[4] Eckert D., Buhl S., Weber S., Jager R., Schorle H.: “The AP-2 family of transcription factors”. Genome Biol., 2005, 6, 246.

[5] Mitchell P.J., Timmons P.M., Hebert J.M., Rigby P.W., Tjian R.: “Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis”. Genes Dev., 1991, 5, 105.

[6] Mitchell P.J., Wang C., Tjian R.: “Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen”. Cell, 1987, 50, 847.

[7] Nordentoft I., Dyrskjøt L., Bødker J.S.,Wild P.J., Hartmann A., Bertz S., et al.: “Increased expression of trans cription factor TFAP2alpha correlates with chemosensitivity in advanced bladder cancer”. BMC Cancer, 2011, 11, 135.

[8] Woodfield G.W., Chen Y., Bair T.B., Domann F.E., Weigel R.J.: “Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells”. Genes Chromosomes Cancer, 2010, 49, 948.

[9] Ugi S, Nishio Y, Yamamoto H., Ikeda K., Kobayashi M., Tsukada S., et al.: “Relation of the expression of transcriptional factor TFAP2B to that of adipokines in subcutaneous and omental adipose tissues”. Obesity (Silver Spring), 2010, 18, 1277.

[10] Deng W.G., Jayachandran G., Wu G., Xu K., Roth J.A., Ji L.: “Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells”. J. Biol. Chem., 2007, 282, 26460.

[11] Alberti K.G., Zimmet P., Shaw J.: “The metabolic syndrome—a new worldwide definition”. Lancet, 2005, 366, 1059.

[12] Cowey S., Hardy R.W.: “The metabolic syndrome: A high-risk state for cancer?” Am. J. Pathol., 2006, 169, 1505.

[13] Kerem M., Ferahkose Z., Yilmaz U.T., Pasaoglu H., Ofluoglu E., Bedirli A., et al.: “Adipokines and ghrelin in gastric cancer cachexia”. World J. Gastroenterol., 2008, 14, 3633.

[14] Hietala K.A., Kosma V.M., Syrjanen K.J., Syrjanen S.M., Kellokoski J.K.: “Correlation of MIB-1 antigen expression with transcription factors Skn-1, Oct-1, AP-2, and HPV type in cervical intraepithelial neoplasia”. J. Pathol., 1997, 183, 305.

[15] Anttila M.A., Kellokoski J.K., Moisio K.I., Mitchell P.J., Saarikoski S., Syrjänen K., Kosma V.M.: “Expression of transcription factor AP- 2alpha predicts survival in epithelial ovarian cancer”. Br. J. Cancer, 2000, 82, 1974.

[16] Sood A.K., Buller R.E., Burger R.A., Dawson J.D., Sorosky J.I., Berman M.: “Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome”. Obstet. Gynecol., 1997, 90, 441.

[17] Wajchenberg B.L.: “Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome”. Endocr. Rev., 2000, 21, 697.

[18] Petridou E., Belechri M., Dessypris N., Koukoulomatis P., Diakomanolis E., Spanos E., Trichopoulos D.: “Leptin and body mass index in relation to endometrial cancer risk”. Ann. Nutr. Metab., 2002, 46, 147.

[19] Cymbaluk A., Chudecka-Glaz A., Rzepka-Gorska I.: “Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 136, 74.

[20] Dal Maso L., Augustin L.S., Karalis A., Talamini R., Franceschi S., Trichopoulos D., et al.: “Circulating adiponectin and endometrial cancer risk”. J. Clin. Endocrinol. Metab., 2004, 89, 1160.

[21] Soliman P.T., Wu D., Tortolero-Luna G., Schmeler K.M., Slomovitz B.M., Bray M.S., et al.: “Association between adiponectin, insulin resistance, and endometrial cancer”. Cancer, 2006, 106, 2376.

[22] Seth D., Garmo H., Wigertz A., Holmberg L., Hammar N., Jungner I., et al.: “Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study”. Int. J. Mol. Epidemiol. Genet., 2012, 3, 122.

[23] Niloff J.M., Klug T.L., Schaetzl E., Zurawski V.R. Jr., Knapp R.C, Bast R.C. Jr.: “Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix”. Am. J. Obstet. Gynecol., 1984, 148, 1057.

[24] Dotters D.J.: “Preoperative CA 125 in endometrial cancer: is it useful?” Am. J. Obstet. Gynecol., 2000, 182, 1328.

[25] Yildiz A., Yetimalar H., Kasap B., Aydin C., Tatar S., Soylu F., Yildiz F.S.: “Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 164, 191.

[26] Lo S.S., Cheng D.K., Ng T.Y., Wong L.C., Ngan H.Y.: “Prognostic significance of tumour markers in endometrial cancer”. Tumour Biol., 1997, 18, 241